Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

The interaction of the Chrna5 D398N variant with developmental nicotine exposure.

O'Neill HC, Wageman CR, Sherman SE, Grady SR, Marks MJ, Stitzel JA.

Genes Brain Behav. 2018 Sep;17(7):e12474. doi: 10.1111/gbb.12474. Epub 2018 Apr 17.

PMID:
29573323
2.

Deletion of lynx1 reduces the function of α6* nicotinic receptors.

Parker RL, O'Neill HC, Henley BM, Wageman CR, Drenan RM, Marks MJ, Miwa JM, Grady SR, Lester HA.

PLoS One. 2017 Dec 5;12(12):e0188715. doi: 10.1371/journal.pone.0188715. eCollection 2017.

3.

TC299423, a Novel Agonist for Nicotinic Acetylcholine Receptors.

Wall TR, Henderson BJ, Voren G, Wageman CR, Deshpande P, Cohen BN, Grady SR, Marks MJ, Yohannes D, Kenny PJ, Bencherif M, Lester HA.

Front Pharmacol. 2017 Sep 26;8:641. doi: 10.3389/fphar.2017.00641. eCollection 2017.

4.

Risk Estimates for Atherosclerotic Cardiovascular Disease in Adults With Congenital Heart Disease.

Lui GK, Rogers IS, Ding VY, Hedlin HK, MacMillen K, Maron DJ, Sillman C, Romfh A, Dade TC, Haeffele C, Grady SR, McElhinney DB, Murphy DJ, Fernandes SM.

Am J Cardiol. 2017 Jan 1;119(1):112-118. doi: 10.1016/j.amjcard.2016.09.023. Epub 2016 Sep 30.

5.

Evaluation of the Nicotinic Acetylcholine Receptor-Associated Proteome at Baseline and Following Nicotine Exposure in Human and Mouse Cortex.

McClure-Begley TD, Esterlis I, Stone KL, Lam TT, Grady SR, Colangelo CM, Lindstrom JM, Marks MJ, Picciotto MR.

eNeuro. 2016 Aug 16;3(4). pii: ENEURO.0166-16.2016. doi: 10.1523/ENEURO.0166-16.2016. eCollection 2016 Jul-Aug.

6.

Chronic treatment with varenicline changes expression of four nAChR binding sites in mice.

Marks MJ, O'Neill HC, Wynalda-Camozzi KM, Ortiz NC, Simmons EE, Short CA, Butt CM, McIntosh JM, Grady SR.

Neuropharmacology. 2015 Dec;99:142-55. doi: 10.1016/j.neuropharm.2015.07.019. Epub 2015 Jul 17.

7.

Density of α4β2* nAChR on the surface of neurons is modulated by chronic antagonist exposure.

Zambrano CA, Short CA, Salamander RM, Grady SR, Marks MJ.

Pharmacol Res Perspect. 2015 Mar;3(2):e00111. doi: 10.1002/prp2.111.

8.

Presynaptic GABAB autoreceptor regulation of nicotinic acetylcholine receptor mediated [(3)H]-GABA release from mouse synaptosomes.

McClure-Begley TD, Grady SR, Marks MJ, Collins AC, Stitzel JA.

Biochem Pharmacol. 2014 Sep 1;91(1):87-96. doi: 10.1016/j.bcp.2014.06.010. Epub 2014 Jun 19.

9.

α6β2*-subtype nicotinic acetylcholine receptors are more sensitive than α4β2*-subtype receptors to regulation by chronic nicotine administration.

Marks MJ, Grady SR, Salminen O, Paley MA, Wageman CR, McIntosh JM, Whiteaker P.

J Neurochem. 2014 Jul;130(2):185-98. doi: 10.1111/jnc.12721. Epub 2014 Apr 19.

10.

Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function α6* nAChRs.

Wang Y, Lee JW, Oh G, Grady SR, McIntosh JM, Brunzell DH, Cannon JR, Drenan RM.

J Neurochem. 2014 Apr;129(2):315-27. doi: 10.1111/jnc.12616. Epub 2013 Dec 13.

11.

Effectiveness of nicotinic agonists as desensitizers at presynaptic α4β2- and α4α5β2-nicotinic acetylcholine receptors.

Wageman CR, Marks MJ, Grady SR.

Nicotine Tob Res. 2014 Mar;16(3):297-305. doi: 10.1093/ntr/ntt146. Epub 2013 Sep 19.

12.

Exploring the nicotinic acetylcholine receptor-associated proteome with iTRAQ and transgenic mice.

McClure-Begley TD, Stone KL, Marks MJ, Grady SR, Colangelo CM, Lindstrom JM, Picciotto MR.

Genomics Proteomics Bioinformatics. 2013 Aug;11(4):207-18. doi: 10.1016/j.gpb.2013.05.005. Epub 2013 Jul 25.

13.

Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.

Quik M, Campos C, Grady SR.

Biochem Pharmacol. 2013 Oct 15;86(8):1153-62. doi: 10.1016/j.bcp.2013.06.027. Epub 2013 Jul 4.

14.

A role for α4(non-α6)* nicotinic acetylcholine receptors in motor behavior.

Soll LG, Grady SR, Salminen O, Marks MJ, Tapper AR.

Neuropharmacology. 2013 Oct;73:19-30. doi: 10.1016/j.neuropharm.2013.05.001. Epub 2013 May 17.

15.

Mice expressing the ADNFLE valine 287 leucine mutation of the Β2 nicotinic acetylcholine receptor subunit display increased sensitivity to acute nicotine administration and altered presynaptic nicotinic receptor function.

O'Neill HC, Laverty DC, Patzlaff NE, Cohen BN, Fonck C, McKinney S, McIntosh JM, Lindstrom JM, Lester HA, Grady SR, Marks MJ.

Pharmacol Biochem Behav. 2013 Jan;103(3):603-21. doi: 10.1016/j.pbb.2012.10.014. Epub 2012 Nov 1.

16.

CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation.

Sala M, Braida D, Pucci L, Manfredi I, Marks MJ, Wageman CR, Grady SR, Loi B, Fucile S, Fasoli F, Zoli M, Tasso B, Sparatore F, Clementi F, Gotti C.

Br J Pharmacol. 2013 Feb;168(4):835-49. doi: 10.1111/j.1476-5381.2012.02204.x.

17.

α6* nicotinic acetylcholine receptor expression and function in a visual salience circuit.

Mackey ED, Engle SE, Kim MR, O'Neill HC, Wageman CR, Patzlaff NE, Wang Y, Grady SR, McIntosh JM, Marks MJ, Lester HA, Drenan RM.

J Neurosci. 2012 Jul 25;32(30):10226-37. doi: 10.1523/JNEUROSCI.0007-12.2012.

18.

Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice.

Quik M, Park KM, Hrachova M, Mallela A, Huang LZ, McIntosh JM, Grady SR.

Neuropharmacology. 2012 Sep;63(3):450-9. doi: 10.1016/j.neuropharm.2012.04.029. Epub 2012 May 3.

19.

Regulation of the distribution and function of [(125)I]epibatidine binding sites by chronic nicotine in mouse embryonic neuronal cultures.

Zambrano CA, Salamander RM, Collins AC, Grady SR, Marks MJ.

J Pharmacol Exp Ther. 2012 Aug;342(2):245-54. doi: 10.1124/jpet.112.192542. Epub 2012 Apr 24.

20.

A novel α-conotoxin MII-sensitive nicotinic acetylcholine receptor modulates [(3) H]-GABA release in the superficial layers of the mouse superior colliculus.

McClure-Begley TD, Wageman CR, Grady SR, Marks MJ, McIntosh JM, Collins AC, Whiteaker P.

J Neurochem. 2012 Jul;122(1):48-57. doi: 10.1111/j.1471-4159.2012.07759.x. Epub 2012 May 9.

21.

Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.

Ortiz NC, O'Neill HC, Marks MJ, Grady SR.

Nicotine Tob Res. 2012 Jun;14(6):711-9. doi: 10.1093/ntr/ntr284. Epub 2012 Jan 12.

22.

Low concentrations of nicotine differentially desensitize nicotinic acetylcholine receptors that include α5 or α6 subunits and that mediate synaptosomal neurotransmitter release.

Grady SR, Wageman CR, Patzlaff NE, Marks MJ.

Neuropharmacology. 2012 Apr;62(5-6):1935-43. doi: 10.1016/j.neuropharm.2011.12.026. Epub 2012 Jan 2.

23.

Nicotinic cholinergic mechanisms causing elevated dopamine release and abnormal locomotor behavior.

Cohen BN, Mackey ED, Grady SR, McKinney S, Patzlaff NE, Wageman CR, McIntosh JM, Marks MJ, Lester HA, Drenan RM.

Neuroscience. 2012 Jan 3;200:31-41. doi: 10.1016/j.neuroscience.2011.10.047. Epub 2011 Nov 4.

24.

α4β2 nicotinic acetylcholine receptors on dopaminergic neurons mediate nicotine reward and anxiety relief.

McGranahan TM, Patzlaff NE, Grady SR, Heinemann SF, Booker TK.

J Neurosci. 2011 Jul 27;31(30):10891-902. doi: 10.1523/JNEUROSCI.0937-11.2011.

25.

Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.

Quik M, Perez XA, Grady SR.

Biochem Pharmacol. 2011 Oct 15;82(8):873-82. doi: 10.1016/j.bcp.2011.06.001. Epub 2011 Jun 13. Review.

26.

Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.

Huang LZ, Grady SR, Quik M.

J Pharmacol Exp Ther. 2011 Sep;338(3):932-41. doi: 10.1124/jpet.111.182949. Epub 2011 Jun 10.

27.

Nicotine-mediated activation of dopaminergic neurons in distinct regions of the ventral tegmental area.

Zhao-Shea R, Liu L, Soll LG, Improgo MR, Meyers EE, McIntosh JM, Grady SR, Marks MJ, Gardner PD, Tapper AR.

Neuropsychopharmacology. 2011 Apr;36(5):1021-32. doi: 10.1038/npp.2010.240. Epub 2011 Feb 2.

28.

Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors.

Drenan RM, Grady SR, Steele AD, McKinney S, Patzlaff NE, McIntosh JM, Marks MJ, Miwa JM, Lester HA.

J Neurosci. 2010 Jul 21;30(29):9877-89. doi: 10.1523/JNEUROSCI.2056-10.2010.

29.

Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors.

Grady SR, Drenan RM, Breining SR, Yohannes D, Wageman CR, Fedorov NB, McKinney S, Whiteaker P, Bencherif M, Lester HA, Marks MJ.

Neuropharmacology. 2010 Jun;58(7):1054-66. doi: 10.1016/j.neuropharm.2010.01.013. Epub 2010 Jan 28.

30.

Dopamine D2-receptor activation elicits akinesia, rigidity, catalepsy, and tremor in mice expressing hypersensitive {alpha}4 nicotinic receptors via a cholinergic-dependent mechanism.

Zhao-Shea R, Cohen BN, Just H, McClure-Begley T, Whiteaker P, Grady SR, Salminen O, Gardner PD, Lester HA, Tapper AR.

FASEB J. 2010 Jan;24(1):49-57. doi: 10.1096/fj.09-137034. Epub 2009 Aug 31.

31.

Mouse striatal dopamine nerve terminals express alpha4alpha5beta2 and two stoichiometric forms of alpha4beta2*-nicotinic acetylcholine receptors.

Grady SR, Salminen O, McIntosh JM, Marks MJ, Collins AC.

J Mol Neurosci. 2010 Jan;40(1-2):91-5. doi: 10.1007/s12031-009-9263-y. Epub 2009 Aug 20.

32.

John Daly's compound, epibatidine, facilitates identification of nicotinic receptor subtypes.

Marks MJ, Laverty DS, Whiteaker P, Salminen O, Grady SR, McIntosh JM, Collins AC.

J Mol Neurosci. 2010 Jan;40(1-2):96-104. doi: 10.1007/s12031-009-9264-x. Epub 2009 Aug 12.

33.

Evaluation of structurally diverse neuronal nicotinic receptor ligands for selectivity at the alpha6( *) subtype.

Breining SR, Bencherif M, Grady SR, Whiteaker P, Marks MJ, Wageman CR, Lester HA, Yohannes D.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4359-63. doi: 10.1016/j.bmcl.2009.05.085. Epub 2009 May 27.

34.

Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain.

Marks MJ, Wageman CR, Grady SR, Gopalakrishnan M, Briggs CA.

Biochem Pharmacol. 2009 Oct 1;78(7):795-802. doi: 10.1016/j.bcp.2009.05.022. Epub 2009 May 27.

35.

Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release.

Grady SR, Moretti M, Zoli M, Marks MJ, Zanardi A, Pucci L, Clementi F, Gotti C.

J Neurosci. 2009 Feb 18;29(7):2272-82. doi: 10.1523/JNEUROSCI.5121-08.2009.

36.

The road to discovery of neuronal nicotinic cholinergic receptor subtypes.

Collins AC, Salminen O, Marks MJ, Whiteaker P, Grady SR.

Handb Exp Pharmacol. 2009;(192):85-112. doi: 10.1007/978-3-540-69248-5_4. Review.

PMID:
19184647
37.

Localized low-level re-expression of high-affinity mesolimbic nicotinic acetylcholine receptors restores nicotine-induced locomotion but not place conditioning.

Mineur YS, Brunzell DH, Grady SR, Lindstrom JM, McIntosh JM, Marks MJ, King SL, Picciotto MR.

Genes Brain Behav. 2009 Apr;8(3):257-66. doi: 10.1111/j.1601-183X.2008.00468.x. Epub 2008 Dec 11.

38.

In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors.

Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa JM, Bupp S, Heintz N, McIntosh JM, Bencherif M, Marks MJ, Lester HA.

Neuron. 2008 Oct 9;60(1):123-36. doi: 10.1016/j.neuron.2008.09.009.

39.

Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function.

Perez XA, Bordia T, McIntosh JM, Grady SR, Quik M.

Mol Pharmacol. 2008 Sep;74(3):844-53. doi: 10.1124/mol.108.048843. Epub 2008 Jun 26.

40.

Nicotine-induced dystonic arousal complex in a mouse line harboring a human autosomal-dominant nocturnal frontal lobe epilepsy mutation.

Teper Y, Whyte D, Cahir E, Lester HA, Grady SR, Marks MJ, Cohen BN, Fonck C, McClure-Begley T, McIntosh JM, Labarca C, Lawrence A, Chen F, Gantois I, Davies PJ, Petrou S, Murphy M, Waddington J, Horne MK, Berkovic SF, Drago J.

J Neurosci. 2007 Sep 19;27(38):10128-42.

41.

The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.

Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, Collins AC, Marks MJ.

Biochem Pharmacol. 2007 Oct 15;74(8):1235-46. Epub 2007 Jul 27. Review.

42.

Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path.

Nashmi R, Xiao C, Deshpande P, McKinney S, Grady SR, Whiteaker P, Huang Q, McClure-Begley T, Lindstrom JM, Labarca C, Collins AC, Marks MJ, Lester HA.

J Neurosci. 2007 Aug 1;27(31):8202-18.

43.

Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum.

Bordia T, Grady SR, McIntosh JM, Quik M.

Mol Pharmacol. 2007 Jul;72(1):52-61. Epub 2007 Apr 4.

PMID:
17409284
44.

Pharmacology of alpha-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice.

Salminen O, Drapeau JA, McIntosh JM, Collins AC, Marks MJ, Grady SR.

Mol Pharmacol. 2007 Jun;71(6):1563-71. Epub 2007 Mar 6.

PMID:
17341654
45.

Guidelines on nicotine dose selection for in vivo research.

Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, Donny EC, Gardiner PS, Grady SR, Heberlein U, Leonard SS, Levin ED, Lukas RJ, Markou A, Marks MJ, McCallum SE, Parameswaran N, Perkins KA, Picciotto MR, Quik M, Rose JE, Rothenfluh A, Schafer WR, Stolerman IP, Tyndale RF, Wehner JM, Zirger JM.

Psychopharmacology (Berl). 2007 Feb;190(3):269-319. Epub 2006 Aug 9. Review.

PMID:
16896961
46.

Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates.

McCallum SE, Parameswaran N, Perez XA, Bao S, McIntosh JM, Grady SR, Quik M.

J Neurochem. 2006 Feb;96(4):960-72. Epub 2006 Jan 12.

47.

Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage.

McCallum SE, Parameswaran N, Bordia T, McIntosh JM, Grady SR, Quik M.

Mol Pharmacol. 2005 Sep;68(3):737-46. Epub 2005 Jun 2.

PMID:
15933214
48.

The subunit composition and pharmacology of alpha-Conotoxin MII-binding nicotinic acetylcholine receptors studied by a novel membrane-binding assay.

Salminen O, Whiteaker P, Grady SR, Collins AC, McIntosh JM, Marks MJ.

Neuropharmacology. 2005 Apr;48(5):696-705.

PMID:
15814104
49.

Long-term nicotine treatment decreases striatal alpha 6* nicotinic acetylcholine receptor sites and function in mice.

Lai A, Parameswaran N, Khwaja M, Whiteaker P, Lindstrom JM, Fan H, McIntosh JM, Grady SR, Quik M.

Mol Pharmacol. 2005 May;67(5):1639-47. Epub 2005 Jan 28.

PMID:
15681595
50.

Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice.

Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC, Grady SR.

Mol Pharmacol. 2004 Jun;65(6):1526-35.

PMID:
15155845

Supplemental Content

Loading ...
Support Center